Natera Inc (NTRA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Outlook ... [Yahoo! Finance]
Natera, Inc. (NTRA)
Last natera, inc. earnings: 2/26 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.natera.com
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Revenue: $666 million in Q4 2025, representing approximately 40% growth over Q4 2024. Gross Margin: 66.9% in Q4 2025, with an organic gross margin of 63.7% after excluding revenue true-ups. Cash Flow: Over $107 million generated in 2025. MRD Clinical Units: 225,000 tests processed in Q4 2025, a 56% increase compared to Q4 2024. DSOs (Days Sales Outstanding): 47 days in Q4 2025, improved from 68 days in Q4 2024. Net Income: Achieved in Q4 2025, aided by a deferred tax item related to the Foresight acquisition. Cash and Securities: Over $1 billion on the balance sheet. 2026 Revenue Guidance: Expected between $2.62 billion and $2.7 billion. 2026 Gross Margin Guidance: Expected between 63% and 65%. Operating Expenses (OpEx): Expected to grow about 9.5% in 2026. Warning! GuruFocus has detected 3 Warning Signs with NTRA. Is NTRA fairly valued? Test your thesis with our free DCF calculator. Release Date: February 26, 2026
Show less
Read more
Impact Snapshot
Event Time:
NTRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NTRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NTRA alerts
High impacting Natera, Inc. news events
Weekly update
A roundup of the hottest topics
NTRA
News
- Natera (NTRA) is now covered by William Blair. They set an "outperform" rating on the stock.MarketBeat
- Natera Highlights Positive Interim Futility Analysis from Allogene Therapeutics’ MRD-Guided ALPHA3 Trial in Large B-Cell LymphomaBusiness Wire
- Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related PatentsBusiness Wire
- Natera Inc. (NTRA): Upside Potential Pulls Billionaire Stan Druckenmiller [Yahoo! Finance]Yahoo! Finance
- 20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology PlatformBusiness Wire
NTRA
Earnings
- 2/26/26 - Miss
NTRA
Sec Filings
- 4/9/26 - Form 3
- 4/8/26 - Form 4
- 4/3/26 - Form 4
- NTRA's page on the SEC website